Related Experiment Video

Updated: Mar 10, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma

Elizabeth Aughey1, Noel Estrada-Merly2, Othman Salim Akhtar2

  • 1Medical College of Wisconsin Affiliated Hospitals Graduate Medical Education, Milwaukee, Wisconsin, USA.

British Journal of Haematology
|March 9, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
PROsbispecific antibodydistressmultiple myelomatalquetamab

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
306